Results 131 to 140 of about 27,075 (224)

AZD6738 (Ceralasertib) Enhances Trifluridine's Antitumor Effect in 5‐FU–Resistant Colorectal Cancer Cells

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Resistance to 5‐fluorouracil (5‐FU) remains a major obstacle in colorectal cancer (CRC) treatment. Trifluridine (FTD), the active component of TAS‐102, exerts cytotoxicity through DNA incorporation and reportedly remains active in 5‐FU‐resistant tumors, though with limited clinical efficacy.
Shuhei Uehara, Takuya Suzuki, Junki Kato, Hiroyuki Asai, Akira Kato, Shinnosuke Harata, Hajime Ushigome, Yushi Yamakawa, Takahisa Hirokawa, Hiroki Takahashi, Yoichi Matsuo, Shuji Takiguchi   +11 more
wiley   +1 more source

Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models (dataset)

Resistance to olaparib inevitably develops in ovarian cancer (OC) patients, highlighting the necessity for effective strategies to improve its efficacy. Here, we established a novel olaparib-resistant patient-derived xenograft model of high-grade serous ...
Rogalska, Aneta
core  

Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Graphical Highlights Spatiotemporal immune heterogeneity shapes distinct and evolving immune ecosystems in ovarian cancer. Multimodal biomarkers enable biologically informed patient stratification beyond static single‐marker approaches. Precision immunotherapy should match dominant immune barriers across lesions and treatment stages.
Xinfeng Yang, Yida Wang, Haiyue You, Jingyi Gao, Yangkun Feng, Feng Zhang, Yan Zhang, Bing Zhang, Shaojie Zhao, Yanfang Gu   +9 more
wiley   +1 more source

Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age

International Journal of Gynecology &Obstetrics, Volume 174, Issue 3, Page 1151-1171, September 2026.
Abstract Recent advances in cancer screening, diagnosis, and treatment have greatly improved survival rates among women with gynecologic cancers. More survivors now live long enough to experience treatment‐related menopause. Vasomotor symptoms, genitourinary syndrome of menopause, sexual dysfunction, sleep issues, and long‐term risks from estrogen ...
Agnaldo Lopes da Silva‐Filho, Suvarna Khadilkar, Hema Divakar, Chiara Benedetto, Andrea R. Genazzani, Diana Ramos, Elizabete Argale, Enrique Herrera, Martha Hickey   +8 more
wiley   +1 more source

Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic Variants

Cancer Medicine
Introduction Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP‐ribose) polymerase inhibitors. We analyzed real‐world data on the impact of olaparib on survival in metastatic pancreatic cancer patients harboring ...
Michele Milella, Giulia Orsi, Mariacristina diMarco, Lisa Salvatore, Letizia Procaccio, Silvia Noventa, Silvia Bozzarelli, Ingrid Garajova, Enrico Vasile, Guido Giordano, Marina Macchini, Alessandro Cavaliere, Marina Gaule, Francesca Bergamo, Marta Chiaravalli, Andrea Palloni, Riccardo Carloni, Alessandro Bittoni, Monica Niger, Ilario Giovanni Rapposelli, Maria Grazia Rodriquenz, Mario Scartozzi, Stefania Mosconi, Elisa Giommoni, Ilaria Bernardini, Chiara Paratore, Andrea Spallanzani, Katia Bencardino, Laura Forti, Emiliano Tamburini, Sara Lonardi, Aldo Scarpa, Stefano Cascinu, Giampaolo Tortora, Isabella Sperduti, Michele Reni   +35 more
doaj   +1 more source

Volumetric Microsampling for Patient‐Centric Therapeutic Drug Monitoring in Clinical Pharmacology: A Scoping Review

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Accurate drug concentration measurement is essential for precision pharmacotherapy, but conventional therapeutic drug monitoring (TDM) requires venous sampling, increasing patient burden, and potentially limiting participation in TDM and model‐informed precision dosing (MIPD).
Hari Prabhath Tummala, Abbie D. Leino, Nathaniel J. Rhodes, Kevin J. Downes, Marc H. Scheetz, Manjunath P. Pai   +5 more
wiley   +1 more source

Dual‐Drug‐Loaded Liposomes: Design Strategies, Mechanistic Insights, and Therapeutic Applications in Cancer

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Dual‐drug‐loaded liposomes enable the simultaneous delivery of hydrophilic and hydrophobic therapeutics to tumors, enhancing anticancer efficacy and overcoming multidrug resistance. Through rational formulation design and surface functionalization, these systems improve tumor targeting, modulate efflux mechanisms and EMT, and achieve synergistic ...
Neelam Sinha, Rohan Chand Sahu, Rohit Patil, Dinesh Kumar, Ashish Kumar Agrawal   +4 more
wiley   +1 more source

Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas

Occurrence of resistance to olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) approved in ovarian carcinoma, has already been shown in clinical settings.
Marco Bolis, Giovanna Damia, Maya Ridinger, Carmen Ghilardi, Simone Canesi, Massimo Zucchetti, Divora Yemane, Luca Guarrera, Eugenio Scanziani, Ilaria Mengoli, Maria C. Barbera, Alessandra Decio, Robert Fruscio, Ilaria Craparotta, Tommaso Ceruti, Federica Guffanti, Micheal B. Yaffe, Michela Chiappa, Chiara Grasselli, Anju Karki, Jesse C. Patterson, Robin A. Lu   +21 more
core   +1 more source

Cell Death in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 9, September 2026.
Regulated cell death pathways, including apoptosis, necroptosis, pyroptosis, ferroptosis, and autophagy‐dependent cell death, interact with mitochondrial dysfunction, proteostasis failure, lysosomal stress, glial remodeling, and neuroinflammation across major neurodegenerative diseases.
Tianjiao Li, Qian Zhang, Yichen Wu, Ruixue Huang   +3 more
wiley   +1 more source

Isocitrate Dehydrogenase (IDH) Mutations in Hematological Malignancies: Epidemiology, Mechanisms, and Therapeutic Strategies

MedComm – Future Medicine, Volume 5, Issue 3, September 2026.
IDH mutation is an important event in hematological malignancies. This review systematically integrates the basic mechanism of IDH mutations and combines it with the clinical translation of related research progress. It also discusses the application strategies of IDH inhibitors and feasible research directions, with the aim of providing a theoretical ...
Jinkun Xu, Haiying Bai, Lijuan Hu
wiley   +1 more source